EasyM

✈️ The EasyM Team is wheels up!

We’re heading to meeting and are excited to share our latest work with the myeloma community.

📌 Poster # PA-373

“Prospective Study of Peripheral Residual Disease (PRD) Monitoring by Clonotypic Mass Spectrometry (EasyM) in Patients with Newly Diagnosed Multiple Myeloma”

Looking forward to sharing our findings, connecting with colleagues, and exchanging ideas on the future of multiple myeloma research.

Visit our booth or DM us to set up a time to chat - see you in Glasgow! 🤝

🩸💪 ONE WEEK TO DOUBLE YOUR IMPACT!

On September 25 at 2 PM ET, every donation to the EasyM team will be matched by us, meaning your support can go twice as far.

👉 Support the EasyM team: https://lnkd.in/gQMrqUM6

Every donation supports Myeloma Canada - National Page and helps bring us closer to better treatments, better outcomes, and a future where multiple myeloma is no longer life-limiting.

One week. Double the impact. Together, let’s make a difference. ❤️

The EasyM team is excited to be attending the International Myeloma Society (IMS) 2026 Annual Meeting in Glasgow next week! 🎉

We’re looking forward to connecting, learning the latest advances in myeloma research, and having great conversations with the community.

Will you be at IMS 2026? DM us to set up a time to meet, we’d be happy to chat! 🤝

See you in Glasgow!

🩸💪 We’re 50% of the way to our goal!

DOUBLE YOUR IMPACT 🙌

At 2 PM ET on September 25 all donations will be matched by us!

👉 Support the EasyM team: https://support.myeloma.ca/site/TR/MultipleMyelomaMarch/General?pg=team&team_id=8535&fr_id=2014

Every donation supports Myeloma Canada - National Page and brings us closer to better treatments, better outcomes, and a future where multiple myeloma is no longer life-limiting.

Together, let's make a difference ❤️

Early treatment failure after CAR-T: can we identify patients at risk?

A new study of patients with relapsed/refractory multiple myeloma treated with ciltacabtagene autoleucel (cilta-cel) found that:

• Prior BCMA-directed therapy, extramedullary disease, and CAR-HEMATOTOX ≥2 were independent predictors of early progression or death.
• MRD positivity at 3 months was associated with a significantly higher risk of early treatment failure.
• Less than complete response on FDG PET/CT at 3 months was also strongly associated with early treatment failure.

These findings highlight the potential value of early and sensitive disease monitoring after CAR-T, particularly for identifying patients who may need closer follow-up or new therapeutic strategies.

📄 Read the study: https://onlinelibrary.wiley.com/doi/10.1002/ajh.70425

🩸 September is Blood Cancer Awareness Month 🩸

Did you know Multiple Myeloma is the 2nd most common blood cancer in the world?

This month and always, we pledge to:

- Stand with patients and families
- Raise awareness of Multiple Myeloma
- Drive research forward

Every share, every conversation, and every act of support brings us one step closer to a future with better options for all.

Step Up for Canadians Living with Multiple Myeloma 🩸💪

On September 27, the EasyM team will join the Kitchener-Waterloo Multiple Myeloma March in support of
Myeloma Canada - National Page


Your donation helps:
- Advance research toward better treatments and outcomes
- Strengthen patient advocacy and access to new therapies

Double your impact ‼️

Donate by September 25 and your contribution could go twice as far.
At 2 PM ET on September 25, 2026, we will match the total amount raised by our team at that time, effectively doubling every donation made.

Every donation brings us closer to better treatments, better outcomes, and a future where multiple myeloma is no longer life-limiting.

Support our team and help us reach our goal:
https://support.myeloma.ca/site/TR/MultipleMyelomaMarch/General?pg=team&team_id=8535&fr_id=2014

Together, every step makes a difference.

Today the FDA announced approval of Zenbexus (iberdomide), in combination with Darzalex (daratumumab) and dexamethasone, for patients whose multiple myeloma has returned after one or more previous treatments. Here's what patients should know: https://bit.ly/4qhcO5X

📈 Sustained MRD negativity matters in newly diagnosed multiple myeloma.

In a cohort of 335 patients, sustained MRD-negative status was associated with significantly better PFS, while even one MRD-positive result predicted worse outcomes.

The study suggests that durable MRD negativity may outweigh the impact of high-risk cytogenetics and highlights the clinical value of serial MRD monitoring.

Read the abstract here: https://ascopubs.org/doi/pdf/10.1200/JCO.2026.44.16_suppl.7570

Did you know? 💡

Blood-based monitoring is an emerging approach in multiple myeloma care.

EasyM is available in Canada and the United States.

If you have multiple myeloma and would like to learn more about blood-based monitoring, speak with your healthcare provider to discuss which monitoring options may be appropriate for your individual care.

Learn more on our website: www.easym.com